Kazem Anvari; Abdolazim Sedighi Pashaki; Mahmoud Reza Kalantari; Mehdi Seilanian Toosi; Mohammad Reza Ghavam Nasiri; Hamid Reza Raziee
Volume 4, Issue 1 , January 2009, , Pages 32-37
Abstract
Background and Objective: Approximately half of patients with diffuse large B-cell lymphoma are cured with current chemotherapy regimens. The purpose of this study was to evaluate Bax and Bcl2 expression and their relationship with the response to chemotherapy. Materials and Methods This study ...
Read More
Background and Objective: Approximately half of patients with diffuse large B-cell lymphoma are cured with current chemotherapy regimens. The purpose of this study was to evaluate Bax and Bcl2 expression and their relationship with the response to chemotherapy. Materials and Methods This study was a prospective analysis on 44 patients with diffuse large B-cell lymphoma. Their specimens were stained with immunohistochemistery method for Bax and Bcl2. The relationship between Bax/Bcl2 expression and the response to chemotherapy as well as some other prognostic factors were assessed. Results: Out of 44 patients, 29 were Bax+ and 15 Bax-, 31 Bcl2+ and 13 Bcl2-. We found a statistically significant relationship between IPI score and the response to chemotherapy (P = 0.002). The response rates were relatively better (but not significant) in cases with Bax + compared to Bax – and in patients with Bcl2- compared to Bcl2 + tumors. The combination of immunohistochemistery results for Bcl2 and Bax could predict relatively higher response rates in a way that those with Bax+ Bcl2- had a higher response compared to Bax- Bcl2+ ( 57%% VS.22%, p=0.15). Conclusion: Although we found a relatively higher responses in our cases with Bax + vs. Bax - and in those with Bcl2- vs. Bcl2 +, the differences were not statistically significant. We suggest further studies to confirm whether the Bcl2 and Bax expressions have any effect on the response to chemotherapy and whether they could be considered as predictor factors for chemotherapy response.
Mehdi Seilanian Toosi; Jalil Tavakkol Afshar; Mohamad Reza Ghavam Nassiri; Mona Malekzadeh Moghani; Houshang Rafatpanah; Azam Brook
Volume 2, Issue 2 , April 2007, , Pages 59-66
Abstract
Background and Objective: Host genetic factors such as cytokine gene polymorphisms as well as Helicobacter pylori (H. pylori) infection have been found to be associated with gastric cancer risk . Interleukin 1 is a pro-inflammatory cytokine involved in H. pylori-induced gastric inflammation. Therefore, ...
Read More
Background and Objective: Host genetic factors such as cytokine gene polymorphisms as well as Helicobacter pylori (H. pylori) infection have been found to be associated with gastric cancer risk . Interleukin 1 is a pro-inflammatory cytokine involved in H. pylori-induced gastric inflammation. Therefore, we analyzed the association between IL-1β and IL-1-RN polymorphisms and gastric cancer in Persian residents in north-eastern Iran. Methods: In a case-control study, the genotyping was carried out by PCR-RFLP in 109 gastric cancer patients and 101 randomly-selected healthy controls. The polymorphic sites include promoter region of IL-1β at 511 (C-T transition) position and IL-RN VNTR H. pylori infection was determined by ELISA assay in patients. Results: No significant differences were observed in the allele and genotype frequency of IL-1β-511 and IL-1RN VNTR between patients and control. Genotype frequencies in healthy controls were not significantly different from gastric cancer cases in separate histological types (intestinal or diffuse). IL- 1β-511 CT genotype frequency was significantly higher among healthy subjects than H. pylori positive gastric cancer patients (41.6% vs. 20%, p = 0.01, OR 0.30, 95% CI: 0.11-0.76). Meanwhile, relatively higher frequency of IL-1β-511 T genotype was observed among H. pylori positive cases as compared to healthy controls (42.9% vs. 26.7%, p = 0.06, OR 2.16, 95% CI: 0.96-4.8) Conclusion: Our results suggest the association between IL-1β-511 polymorphism and H. pylori infection and their contribution to the risk of gastric cancer. While IL-1β-511 CT genotype has a protective effect against H. pylori associated gastric carcinoma, IL-1β-511 TT may increase the risk.